Immune response of primary and booster immunity of SARS-CoV-2 vaccination among patients with chronic liver disease

Ruixin Song1#, Chao Yang2#, Jiayin Wang1#, Qianqian Li2#, Jing Chen1#, Kai Sun3, Hongmin Lv2, Yankai Yang2, Jing Liang2, Qing Ye2, YanYing Gao2, Jun Li2, Ying Li2, Junqing Yan2, Ying Liu2, Tao Wang2, Changen Liu2, Fei Wang2, Weili Yin2, Huiling Xiang2*

1. The Third Central Clinical College of Tianjin Medical University, Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease

2. Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin

Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease

3. Tianjin Hongqiao Hospital, Tianjin, China

: Ruixin Song, Chao Yang , Jiayin Wang , Qianqian Li, Jing Chen share co-first authorship

Financial support

1. Sponsored by Tianjin Health Research Project. (No : TJWJ2022XK029)

2. Funded by Tianjin Key Medical Discipline (Specialty) Construction Project. (No :

TJYXZDXK-034A)

Abstract

Aim: we examined the humoral immune response and antibody dynamics after primary and booster vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among patients with chronic liver disease (CLD).

Methods: We enrolled patients with confirmed CLD and SARS-CoV-2 vaccination primary or booster immunity. Following primary or booster immunity, serological samples were gathered to detect novel coronavirus neutralizing antibodies (nCoV NTAb) and novel coronavirus spike receptor-binding proteins (nCoV S-RBD).

Results: The positive rate of nCoV NTAb was 60.1% in Primary and 87.6% in Booster (P<0.001). The median level of nCoV NTAb was 11.6 AU/mL in Primary and 31.6 AU/mL in Booster (P<0.001). The positive rate of nCoV S-RBD was 70.0% in Primary and 91.2% in Booster (P<0.001). The median level of nCoV S-RBD was 21.7 AU/mL in Primary and 110.6 AU/mL in Booster (P<0.001). Compared to the antibody level of primary immunity, 21 patients in whom SARS-CoV-2 vaccine antibodies were detected after both primary and booster immunizations showed an increase of 4.4 and 5.9 times in nCoV NTAb and nCoV S-RBD, respectively.

Conclusion: Patients with CLD show improved humoral immune response after completing primary and booster immunity of SARS-CoV-2 vaccines, while booster immunity further improves the positive rate and antibody level of patients with CLD.

Keywords: immune response; primary and booster immunity; SARS-CoV-2; vaccination; chronic liver disease

As of April 2023, 762 million people have been proved to infect Coronavirus Disease 2019 (COVID-19), and 6.9 million people have died all over the world^[1]. Vaccines of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been implemented successively. In the 20-59-year-old age group, BNT162b2 and CoronaVac vaccination avoided mortality after COVID-19 diagnosis by 91.7%^[2]. Those with chronic liver disease (CLD) have congenital and adaptive immune cell suppression^[3], a higher risk of infection and mortality^[4, 5]; hence, SARS-CoV-2 vaccination should be targeted at these patients. After completing the primary immunization for participants with CLD, the positive rate of novel coronavirus neutralizing antibody (nCoV NTAb) and novel coronavirus spike receptor-binding domain antibody (nCoV S-RBD) was 87.8% and 87.8%^[6], respectively. Considering the diminishing effectiveness of vaccines^[7, 8], the World Health Organization (WHO) recommended a booster dose vaccination. Compared to primary immunization of SARS-CoV-2 vaccines, the effectiveness of a booster dose in preventing the occurrence of COVID-19 is 95.3%^[9]. Notably, three doses reduce the hospitalization rate, disease severity, and mortality^[10]. Several studies have discussed the humoral immune response of patients with CLD after primary immunity with SARS-CoV-2 vaccines. However, data regarding booster immunity on the humoral immune response in CLD are yet lacking. This study investigated the humoral immunity and antibody dynamics with SARS-CoV-2 vaccines among CLD after completing primary and booster immunity. Hence, this study contributes to advancing vaccination tactic about SARS-CoV-2.

1. Methods

1.1 Inclusion and exclusion criteria

This study enrolled patients visiting the hepatology outpatient clinic of the Third Central Hospital of Tianjin in China between January 2021 and June 2022. Here are the criteria for inclusion: 1. Age \geq 18 years; 2. CLD diagnosed by clinical data or medical history; 3. Completion of primary immunity or booster immunity of SARS-CoV-2 vaccines; 4. Consent to take part in the research and comply with research procedures.

It was excluded from this study if you were pregnant, lactating, active or previous COVID-19 infection, previously undergone liver transplantation, immunosuppressive or had an immunodeficiency disorder [including human immunodeficiency virus (HIV) infection], the use of systemic immunosuppressive medications, systemic immunoglobulins or immune boosters within the last three months.

1.2 Diagnostic basis of CLD

The definition of CLD is liver disease that lasts more than six months and included chronic liver inflammation, irrespective of cirrhosis. Cirrhosis diagnostic criteria are based on the Cirrhosis Diagnosis and Treatment Guidelines^[11].

1.3 Vaccine types and injection protocol

The types of vaccines in this study included BBIBP-CorV vaccine (Beijing Institute of Biological Products Co., Ltd, China), CoronaVac vaccine (Beijing Sinovac Life Sciences Co., Ltd, China), CanSinoBio Ad5-nCoV vaccine (CanSino Biologics Inc. China), and Zifivax vaccine (CHO cells) (Anhui Zhifei Longcom Biopharmaceutical Co., Ltd, China). The immunization protocol was based on the SARS-CoV-2 immunization Guidelines^[12]. CoronaVac and BBIBP-CorV vaccines are inactivated and require two doses at an interval of 3–8 weeks, with a booster dose at least 6 months apart. CanSinoBio Ad5-nCoV vaccine is an adenovirus vector vaccine that requires one dose; a booster dose is a minimum of six months except the primary dose. The Zifivax vaccine is a recombinant subunit vaccine requiring three doses, 4-8weeks intervals between each dose, and does not require a booster dose.

1.4 Clinical data collection

Clinical data included baseline demographics [age, gender, race, and body mass index (BMI)], liver disease-related situation (etiology, absence or presence cirrhosis, and Child-Pugh class), comorbidity-related situation (hypertension, diabetes, coronary artery disease, asthma, and arrhythmia), SARS-CoV-2 vaccination information (the type of vaccine and the date of completion primary or booster immunity), laboratory examination-related indicators (alanine aminotransferase, aspartate aminotransferase, albumin, gamma-glutamyl transpeptidase, and alkaline phosphatase).

1.5 Assessment of immune response

Serological specimens were collected after completion of primary or booster immunity of SARS-CoV-2 vaccines to detect nCoV NTAb and nCoV S-RBD [competitive combination chemiluminescence immunoassay (CLIA) method by Shenzhen Mindray Bio-Medical Electronics Co., Ltd, China]. Based on the instructions provided by the manufacturer, antibody level over 10.0 AU/mL was thought positive, while antibody level less than 10.0 AU/mL was thought negative.

1.6 Safety assessment

Local and systemic side effects of patients with CLD following primary and booster immunization of SARS-CoV-2 vaccinations were reported. The local side effects at the injection site comprised ache, swelling, redness, induration, pruritus at the injection site, and their severity. Systemic side effects comprised fever, dizziness, fatigue, nausea, vomiting, decreased appetite, myalgia, arthralgia, oropharyngeal pain, cough, allergy, dyspnea, syncope, pruritus (non-injection site), and their severity.

1.7 Statistical analysis

Numerical variables were portrayed by mean (standard deviation) or median (IQR) depending on whether they conformed normal distribution. The frequencies and percentages of each variables were used to represent the categorical variables. Numerical variables were assessed by t-test and nonparametric test to evaluate the Statistical difference. Categorical variables were evaluated for statistically significant differences between groups using Pearson's χ^2 test and Fisher's exact test. P-values below 0.05 were thoughted the statistical difference when using the two-sided test. SPSS 24.0 was applied to the statistical analysis. The images were generated using Origin 2023.

1.8 Ethical Statements

Prior to registration, each participant provided written informed consent. The research is approved by the Ethics Committee of Tianjin Third Central Hospital in China. This research protocol adheres to the ethical guidelines outlined in the 1975 Declaration of Helsinki (Approval number:IRB 2021-027-01).

2. Results

2.1 Baseline demographic and clinical characteristics

316 patients completed SARS-CoV-2 vaccines and were divided into primary and booster immunity groups according to the status of vaccination. In this study, the primary immunity group was referred to as Primary, and the booster immunity group was referred to as Booster. Primary included 203 patients who completed the primary immunity of SARS-CoV-2 vaccination, and Booster included 113 patients who completed booster immunity of SARS-CoV-2 vaccination (Figure 1). The median age of the primary and booster groups was 54.0 (IQR: 42.0-62.0) years and 52.0 (IQR: 42.5-59.5) years (P=0.446). Males accounted for 56.2% and 62.8% in Primary and Booster (P=0.284). Regarding etiology, CLD was caused by hepatitis B virus, and the proportion of hepatitis B was 67.0% and 86.7%, respectively (P=0.001). The median time between primary immunity completion to serological specimen collection was 55 (IQR: 32-102) days, and the median time between booster immunity completion and serological specimen collection was 102 (IQR: 45-145) days (P<0.001) (Table 1).

2.2 Immune response assessment

2.2.1 nCoV NTAb

The positive rate of nCoV NTAb was 60.1% in Primary and 87.6% in Booster (P<0.001) (Table 2 and Figure 2A). A booster

dose increased nCoV NTAb positivity rate by 27.5%. The median level of nCoV NTAb was 11.6 (IQR: 8.1-20.3) AU/mL in Primary and 31.6 (IQR: 15.4-97.0) AU/mL in Booster (P<0.001) (Table 2 and Figure 2B). A booster dose increased the level of nCoV NTAb by 2.7-fold.

Subgroup analysis: The humoral immune response of non-cirrhosis and cirrhosis was compared in Primary and Booster. After Primary, the positive rate of nCoV NTAb was 58.9% and 61.5% in non-cirrhosis and cirrhosis patients (P=0.775), respectively, and the median level was 11.3 (IQR: 7.8-20.3) AU/mL and 12.1 (IQR: 8.6-20.5) AU/mL in non-cirrhosis and cirrhosis (P=0.577), respectively. After Booster, the positive rate of nCoV NTAb was 93.5% and 80.4% in non-cirrhosis and cirrhosis (P=0.045), respectively, and the median level was 31.4 (IQR: 19.5-96.0) AU/mL and 32.3 (IQR: 11.3-99.7) AU/mL in non-cirrhosis and cirrhosis, respectively (P=0.441) (Table 3 and Figure 3A).

2.2.2 nCoV S-RBD

The positive rate of nCoV S-RBD was 70.0% in Primary and 91.2% in Booster (P<0.001) (Table 2 and Figure 2C). A booster dose increased nCoV S-RBD positivity rate by 21.2%. The median level of nCoV S-RBD was 21.7 (IQR: 7.7-63.0) AU/mL in Primary and 110.6 (IQR: 31.0-285.4) AU/mL in Booster (P<0.001) (Table 2 and Figure 2D). A booster dose increased the level of nCoV S-RBD by 5.1 times.

Subgroup analysis: After Primary, the positive rate of nCoV S-RBD was 66.4% and 74.0% (P=0.284), and the median level was 17.6 (IQR: 7.1-50.3) AU/mL and 26.5 (IQR: 9.7-69.0) AU/mL in non-cirrhosis and cirrhosis, respectively (P=0.123). After Booster, the positive rate of nCoV S-RBD was 98.4% and 82.4% (P=0.008), and the median level was 102.9 (IQR: 50.4-286.9) AU/mL and 118.8 (IQR: 17.3-284.6) AU/mL in non-cirrhosis and cirrhosis, respectively (P=0.483) (Table 3 and Figure 3B).

2.2.3 Antibody dynamics after booster immunity

A total of 21 patients underwent antibody detection of SARS-CoV-2 vaccines after both primary and booster immunity to further confirm the dynamic changes in antibodies after booster immunity. Subsequently, the positive rate of nCoV NTAb increased from 57.1% to 85.7%, and that of nCoV S-RBD increased from 66.7% to 90.5% (Table 4 and Figure 4A). The median level of nCoV NTAb increased from 11.1 (IQR: 8.4-16.0) AU/mL to 48.8 (IQR: 16.8-143.4) AU/mL after booster immunity. The median level of nCoV S-RBD was increased from 24.3 (IQR: 7.2-48.9) AU/mL to 142.5 (IQR: 55.8-424.9) AU/mL (Table 4 and Figure 4B). Compared to the antibody level of primary immunity, the median level of nCoV NTAb and nCoV S-RBD was increased by 4.4 and 5.9 times, respectively. In conclusion, after booster immunity of SARS-CoV-2 vaccine, the positive rate and antibody level in patients with CLD can be further improved based on primary immunity. Among 21 patients, 9 were negative for nCoV NTAb after primary immunity, while 6 cases were transformed positive after booster immunity, and the positive conversion rate of nCoV NTAb was 66.7% (Figure 4C). Furthermore, 7 patients were negative for nCoV S-RBD after primary immunity, while 5 were transformed into positive after booster immunity, and the positive conversion rate was 71.4% (Figure 4D). The positive conversion rate among patients with primary immunity failure was also improved after booster immunity, such that patients with primary immunity failure can acquire immunity to COVID-19.

After primary immunity, 9/21 cases were negative for nCoV NTAb, 7/21 were negative for nCoV S-RBD, and 6/21 patients were negative for both nCoV NTAb and nCoV S-RBD. After primary immunity, the median age of nCoV NTAb-negative patients was 57.0 (IQR: 46.5-66.0) years higher than 53.5 (IQR: 48.8-67.8) years in nCoV NTAb-positive patients, and the proportion of cirrhosis in nCoV NTAb-negative patients was 88.9%, which was higher than 50.0% in nCoV NTAb-positive patients (Table 5). After primary immunity, the median age of nCoV S-RBD-negative patients was 57.0 (IQR: 48.0–74.0) years higher than 53.5 (IQR: 47.8-67.3) years of nCoV S-RBD-positive patients, and the proportion of cirrhosis in nCoV S-RBD-negative patients was 85.7% higher than 57.1% in nCoV S-RBD-positive patients (Table 6).

2.3 Safety assessment

After primary immunity, 46/203 (22.7%) participants happened the side effects. Local side effects occurred as follows: ache at the injection site (17, 8.4%), pruritus (2, 1.0%) and swelling (1, 0.5%). The most frequent systemic side effect was fatigue (15, 7.4%), followed by nausea (5, 2.5%), fever (4, 2.0%), dizziness (4, 2.0%), myalgia (4, 2.0%), decreased appetite (3, 1.5%), arthralgia (2, 1.0%), and cough (1, 0.5%). Local and systemic adverse reactions after primary immunity were slight and resolved over time.

After booster immunity, 29/113 (25.7%) participants reported the side effects. Local side effects occurred as follows: pain at the injection site (16, 14.2%), pruritus (1, 0.9%). The occurrence of systemic adverse reactions was as follows: fatigue (5, 4.4%), nausea (4, 3.5%), dizziness (3, 2.7%), decreased appetite (2, 1.8%), fever (1, 0.9%), myalgia (1, 0.9%), arthralgia (1, 0.9%), and cough (1, 0.9%). Adverse reactions after booster immunity were slight and self-limiting.

3. Discussion

The epidemic of COVID-19 has threatened public health; it is considered that vaccines have turned a criticial defence step. A prior investigation discovered that the effectiveness of SARS-CoV-2 vaccination was 95% in preventing COVID-19^[13]. The positive rate of nCoV S-RBD was 99.6% in healthy people ^[14]. In another study, two doses of vaccines effectuated a serological conversion of antibodies up to 100% in healthy individuals^[15].

Patients with comorbidities have a high morbidity of COVID-19 and are prone to develop severe illness and death^[16]. The serological conversion rates of nCoV S-RBD in patients with HIV, hematopoietic stem cell transplantation, primary immunodeficiency diseases, chronic lymphocytic leukemia, and solid organ transplantation were 98.7%, 84.7%, 73.3%, 63.3%, and 43.4%, respectively, while that of the healthy control group was 100.0%^[17]. After SARS-CoV-2 vaccination, the inhibitory level of nCoV NTAb in ovarian cancer patients was 83.6%, which was substantially lower than that of the healthy control group (92.9%)^[18]. In this study, the positive serological rates of nCoV NTAb and nCoV S-RBD were 60.1% and 70.0% in CLD after primary immunity. Compared to a previous research^[19], the positive rate of nCoV NTAb in this investigation was lower, which might be due to older age [54.0 (IQR: 42.0-62.0) years *vs.* 47.0 (IQR: 38.0–56.0) years], a larger percentage of cirrhosis (47.3 *vs.* 35.0), and a higher incidence of comorbidity (38.4 *vs.* 12.8).

Nonetheless, the effectiveness of SARS-CoV-2 vaccines diminished over time. The two doses of homologous ChAdOx1 vaccines were 68% effective in preventing COVID-19 at 15–30 days after administration, but no efficacy was detected at 121 days after administration^[20]. Three doses of ZF2001 vaccines in preventing COVID-19 were 75.7% effective in healthy individals in 6 months after administration^[21]. At six months after a booster dose, the positive serological rate of nCoV NTAb was >50%^[22]. The third dose of the BNT162b2 vaccination increased the positive rate of nCoV S-RBD in patients undergoing liver transplantation from 56% to 98%^[23]. After a booster dose, the level of nCoV NTAb in solid tumor patients was improved by three times compared to two doses but remained lower than the healthy control group^[24]. Several investigations have revealed the humoral immune reaction of patients with CLD after primary immunity with SARS-CoV-2 vaccines. However, data regarding booster immunity on the humoral immune reaction in patients with CLD are lacking. In our research, the positive rate of nCoV NTAb was increased by 27.5%, and the antibody level was increased by 2.7 times after booster immunity. The positive rate of nCoV S-RBD was increased by 21.2%, and the antibody level was increased by 5.1-fold after booster immunity. In conclusion, after booster immunity, the humoral immune response in patients with CLD could be improved after primary immunity.

A total of 21 patients underwent antibody detection after both primary and booster immunities to further confirm the dynamic change in antibodies after booster immunity. Subsequently, the positive rate of nCoV NTAb increased from 57.1% to 85.7%, and the positive rate of nCoV S-RBD increased from 66.7% to 90.5%. The median level of nCoV NTAb increased from 11.1 AU/mL to 48.8 AU/mL after booster immunity. The median level of nCoV S-RBD was increased from 24.3 AU/mL to 142.5 AU/mL. Compared to the antibody level of primary immunity, the median level of nCoV NTAb and nCoV S-RBD was increased by 4.4- and 5.9-fold, respectively. Consistent with the literature^[25], patients with CLD improve the humoral immune response after completing booster immunity, and the antibody level of patients with autoimmune hepatitis negative for nCoV S-RBD was increased by 148-fold^[25]. Booster immunity prompted an immune response in liver transplant patients negative for nCoV S-RBD^[23]. 9/21 patients were negative for nCoV NTAb after primary immunity, while 6 cases were transformed positive after booster immunity, and the positive conversion rate of nCoV NTAb was 66.7%. A total of 7 patients were negative for nCoV S-RBD after primary immunity, while 5 cases were transformed positive after booster immunity; the positive conversion rate of nCoV S-RBD was 71.4%. The positive conversion rate among patients with primary immunity failure can be improved after booster immunity, such that patients with primary immunity failure can obtain immunity to COVID-19.

In this study, we executed the subgroup analysis to contrast the immune reaction in patients with non-cirrhosis and cirrhosis in both Primary and Booster groups. Consistent with previous studies^[6, 19], the positive rate and level of nCoV NTAb and nCoV S-RBD had no significant difference between non-cirrhosis and cirrhosis patients in Primary. However, the positive rate of nCoV NTAb and nCoV S-RBD without cirrhosis was higher than that in patients with cirrhosis in Booster. Patients with cirrhosis have congenital and adaptive immune dysfunction^[26] and B cell phenotypic and functional defects^[27]. The number of total T lymphocytes decreases in patients with cirrhosis, while CD4+ and CD8+ T cells expressing apoptosis markers are significantly increased^[28]. These explain the unsatisfactory immune response of patients with cirrhosis after vaccines.

In the current review, we examined the data of 21 patients whose antibodies were negative after primary and booster immunity, respectively. Due to the small samples, statistical analysis was not conducted. We found that patients with negative SARS-CoV-2 antibodies after primary immunity were older and had a high proportion of cirrhosis than those with positive antibodies. After booster immunity, 3 were negative for SARS-CoV-2 antibody, 1 was negative only for nCoV NTAb, and 2 were negative for both nCoV NTAb and nCoV S-RBD. First, 3 cases were cirrhotic and older. In patients with only nCoV NTAb negative, the level of nCoV S-RBD was 11.9 AU/mL. The patient was 74-years-old and had a BMI of 31.6, so the effect of SARS-CoV-2 vaccine was not optimal after booster immunity. Previous studies reported that age and BMI were related to the antibody level ^{[6, 23,} ^{29]}, suggesting that elderly with underlying diseases, such as cirrhosis and obesity, should receive booster vaccinations regularly

to obtain sustained immunity against COVID.

Consistent with the results of current studies^[6, 19], most of the local and systemic side effects in patients with CLD after primary immunity were slight and could be alleviated in this study. The most frequent local and systemic side effect after primary immunity were pain at the injection site and fatigue, respectively. Reportedly, the side effects of healthy individuals are slight after booster immunity^[21, 22]. In this study, we found that the side effects of patients with CLD after booster immunity were mostly mild and self-limited. The most frequent local and systemic adverse reaction after booster immunity were pain at the injection site and fatigue, respectively.

The level of nCoV NTAb predicts vaccine protection^[30]. Regarding the gold standard for the detection of nCoV NTAb^[31, 32], plaque reduction neutralization test (PRNT) involves live virus, and the cell culture and low detection throughput require a high laboratory level and complex procedure. In the present study, competitive combined chemiluminescence immunoassay (CLIA) was used, which has the characteristics of high automation and throughput^[33]. A major target of the SARS-CoV-2 vaccine is the S protein, especially the RBD region on the S protein^[34]. A strong correlation was established between nCoV NTAb and nCoV S-RBD, and it has been confirmed that the detection of nCoV SRBD antibodies is highly-sensitive and specific^[35]. Therefore, two types of antibodies, nCoV NTAb and nCoV S-RBD, were determined in this study.

Nevertheless, there are a few drawbacks in current study. It was a single-center study, and the samples were from the same region. Thus, samples from other regions should be enrolled in the future to make the research results universal. During this study, only the humoral immunity status of patients with CLD who completed SARS-CoV-2 vaccination was estimated, and the cellular immunity status of patients was not evaluated, which is crucial to understand the immunogenicity of SARS-CoV-2 vaccine. Only patients with CLD were included, and healthy individuals were not included as the control group, which did not allow the comparison of the differences in the immunogenicity of SARS-CoV-2 vaccine between patients with CLD and healthy individuals. In the future, we would need to include additional specimens with populations from other areas to confirm our conclusions further.

To date, some countries have started to vaccinate high-risk groups with the fourth dose^[36]; this study provided data support for the formulation of vaccination strategies. In conclusion, patients with CLD improved the humoral immune response after completing primary and booster immunity of SARS-CoV-2 vaccines, while booster immunity further improved the positive rate and antibody level of patients with CLD. Finally, the positive conversion rate among patients with primary immunity failure could be improved after booster immunity.

References

- [1] World Health Organization Coronavirus (COVID-19) Dashboard
 [M].https://covid19.who.int/table Accessed April 5, 2023
- [2] McMenamin M E, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study [J]. The Lancet Infectious Diseases, 2022, 22(10): 1435-1443.
- [3] Li T Y, Yang Y, Zhou G, et al. Immune suppression in chronic hepatitis B infection associated liver disease: A review [J]. World J Gastroenterol, 2019, 25(27): 3527-3537.
- [4] Singh S, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019
 Among Patients With Preexisting Liver Disease in the United States: A Multicenter
 Research Network Study [J]. Gastroenterology, 2020, 159(2): 768-771 e763.
- [5] Williamson E J, Walker A J, Bhaskaran K, et al. Factors associated with

COVID-19-related death using OpenSAFELY [J]. Nature, 2020, 584(7821): 430-436.

- [6] Bakasis A D, Bitzogli K, Mouziouras D, et al. Antibody Responses after SARS-CoV-2
 Vaccination in Patients with Liver Diseases [J]. Viruses, 2022, 14(2).
- [7] Lin D Y, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina [J]. N Engl J Med, 2022, 386(10): 933-941.
- [8] Tartof S Y, Slezak J M, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study [J]. The Lancet, 2021, 398(10309): 1407-1416.
- [9] Moreira E D, Jr., Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine [J]. N Engl J Med, 2022, 386(20): 1910-1921.
- [10] Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study [J]. The Lancet, 2021, 398(10316): 2093-2100.
- [11] Hepatology C S o. Chinese guidelines on the management of liver cirrhosis [J]. Journal of Clinical Hepatology, 2019, 35(11): 2408-2425.
- [12] China N H C o t P s R o. Technical guidelines for vaccination of COVID-19 (version 1)
 [J]. Chinese Journal of Clinical Infectious Diseases, 2021, 14(02): 89-90.
- Polack F P, Thomas S J, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
 Covid-19 Vaccine [J]. N Engl J Med, 2020, 383(27): 2603-2615.
- [14] Uysal E B, Gumus S, Bektore B, et al. Evaluation of antibody response after
 COVID-19 vaccination of healthcare workers [J]. J Med Virol, 2022, 94(3): 1060-1066.
- [15] Chen Y, Yin S, Tong X, et al. Dynamic SARS-CoV-2-specific B-cell and T-cell re-

sponses following immunization with an inactivated COVID-19 vaccine [J]. Clin Microbiol Infect, 2022, 28(3): 410-418.

- [16] Ye C, Zhang S, Zhang X, et al. Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China [J]. J Med Virol, 2020, 92(11): 2821-2829.
- [17] Bergman P, Blennow O, Hansson L, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial [J]. EBioMedicine, 2021, 74(103705).
- [18] Liontos M, Terpos E, Markellos C, et al. Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors [J]. Vaccines (Basel), 2021, 9(10).
- [19] Ai J, Wang J, Liu D, et al. Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study [J]. Clin Gastroenterol Hepatol, 2022, 20(7): 1516-1524.
- [20] Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden [J]. The Lancet, 2022, 399(10327): 814-823.
- [21] Dai L, Gao L, Tao L, et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19
 Vaccine ZF2001 in Adults [J]. N Engl J Med, 2022, 386(22): 2097-2111.
- [22] Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical

trials [J]. Lancet Infectious Diseases, 2022, 22: 483-495.

- [23] Davidov Y, Indenbaum V, Tsaraf K, et al. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients [J]. J Hepatol, 2022, 77(3): 702-709.
- [24] Shroff R T, Chalasani P, Wei R, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors [J]. Nat Med, 2021, 27(11): 2002-2011.
- [25] Hartl J, Rüther D F, Duengelhoef P M, et al. Analysis of the humoral and cellular response after the third COVID-19 vaccination in patient with autoimmune hepatitis [J]. Liver International, 2022, 10.1111.
- [26] Sipeki N, Antal-Szalmas P, Lakatos P L, et al. Immune dysfunction in cirrhosis [J].World J Gastroenterol, 2014, 20(10): 2564-2577.
- [27] Doi H, Iyer T K, Carpenter E, et al. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population [J]. Hepatology, 2012, 55(3): 709-719.
- [28] Marquez M, Fernandez-Gutierrez C, Montes-de-Oca M, et al. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis [J]. Clin Exp Immunol, 2009, 158(2): 219-229.
- [29] Lustig Y, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers [J]. The Lancet Respiratory Medicine, 2021, 9(9): 999-1009.

- [30] Khoury D S, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection [J]. Nat Med, 2021, 27(7): 1205-1211.
- [31] Okba N M A, Muller M A, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus
 2-Specific Antibody Responses in Coronavirus Disease Patients [J]. Emerg Infect Dis,
 2020, 26(7): 1478-1488.
- [32] Perera R A, Mok C K, Tsang O T, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 [J]. Euro Surveillance, 2020, 25(16).
- [33] Muruato A E, Fontes-Garfias C R, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation [J]. Nat Commun, 2020, 11:4059.
- [34] Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines[J]. Semin Immunol, 2020, 50:101422.
- [35] Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patient [J]. Science Immunology, 2020, 5(48).
- [36] Magen O, Waxman J G, Makov-Assif M, et al. Fourth Dose of BNT162b2 mRNA
 Covid-19 Vaccine in a Nationwide Setting [J]. N Engl J Med, 2022, 386(17):
 1603-1614.

Characteristic	Primary	Booster	P-Value
Ν	203	113	
Age,year	54.0(42.0-62.0)	52.0(42.5-59.5)	0.446
Gender, male	114(56.2)	71(62.8)	0.284

Table 1 Baseline demographic and clinical characteristics

Race, Han	199(98.0)	110(97.3)	0.608
BMI	24.7±3.5	24.7±3.5	0.960
Etiology			0.001
HBV	136(67.0)	98(86.7)	
HCV	19(9.4)	4(3.5)	
ALD	10(4.9)	1(0.9)	
AIH, PBC	10(4.9)	6(5.3)	
others	28(13.8)	4(3.5)	
Presence of cirrhosis	96(47.3)	51(45.1)	0.726
Child-Pugh class			0.848
Α	91(94.8)	48(94.1)	
В	2(2.1)	2(3.9)	
С	3(3.1)	1(2.0)	
Comorbidities	78(38.4)	38(33.6)	0.465
Hypertension	48(23.6)	20(17.7)	0.254
Diabetes	30(14.8)	12(10.6)	0.308
CAD	4(2.0)	5(4.4)	0.290
Asthma	4(2.0)	0(0.0)	0.184
Arrhythmia	1(0.5)	1(0.9)	0.680
Vaccine category			0.004
BBIBP-CorV	96(47.3)	45(39.8)	
CoronaVac	92(45.3)	51(45.1)	

CansinoBio	15(7.4)	11(9.7)	
CHO cell Vac	0(0.0)	6(5.3)	
Time interval	55(32-102)	102(45-145)	< 0.001
Liver function			
ALT(U/L)	24.0(17.8-33.0)	22.5(16.0-36.0)	0.327
AST(U/L)	23.0(19.0-29.0)	22.5(18.0-31.0)	0.637
ALB (g/L)	47.8(45.6-49.7)	48.0(46.1-51.6)	0.293
GGT(U/L)	25.0(17.0-46.0)	30.5(17.8-49.5)	0.407
ALP(U/L)	76.0(63.0-94.0)	30.5(17.8-49.5)	0.917

Data was presented as median (interquartile range), Mean±standard deviation, or frequencies(percentage). Vaccine category referred to the type of first dose COVID-19 vaccine. Time interval meant the time (days) between the completion of primary or booster immunity and the collection of serological samples. BMI, Body Mass Index; HBV, Hepatitis B virus; HCV, Hepatitis C virus; ALD, Alcoholic liver disease; AIH, Autoimmune hepatitis; PBC, Primary biliary cholangitis; CAD, Coronary artery disease; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; ALB, Albumin; GGT, Gamma-glutamyl transpeptidase; ALP, Alkaline phosphatase.

 Table 2 The humoral immune response of COVID-19 vaccine in Primary and

 Booster groups among patients with chronic liver disease

	Primary	Booster	P-Value
nCoV NTAb			
The positive rate	122(60.1)	99(87.6)	< 0.001

Antibody level	11.6(8.1-20.3)	31.6(15.4-97.0)	< 0.001
nCoV S-RBD			
The positive rate	142(70.0)	103(91.2)	< 0.001
Antibody level	21.7(7.7-63.0)	110.6(31.0-285.4)	<0.001

Data was presented as median (interquartile range) or frequencies(percentage). Antibody level above 10.0 AU/mL was regarded as positive, while antibody level below 10.0 AU/mL was regarded as negative. nCoV NTAb, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.

Table 3 The humoral immune response of COVID-19 vaccine in Primary and Booster groups among no cirrhosis and cirrhosis patients.

	Prin	mary P-Valu		Booster		P-Valu
	no cirrho- sis	cirrhosis	e	no cirrhosis	cirrhosis	e
n	107	96		62	51	
nCoV NTAb						
The positive rate	63(58.9)	59(61.5)	0.775	58(93.5)	41(80.4)	0.045
Antibody level))	0.577	31.4(19.5-96.0)	32.3(11.3-99.7)	0.441
nCoV S-RBD						
The positive	71(66.4)	71(74.0)	0.284	61(98.4)	42(82.4)	0.008

rate

Antibody level	17.6(7.1-50.3	26.5(9.7-69.0	0.123	102.9(50.4-286.9	118.8(17.3-284.6	0.483
))))	

Data was presented as median (interquartile range) or frequencies(percentage). Antibody level above 10.0 AU/mL was regarded as positive, while antibody level below 10.0 AU/mL was regarded as negative. nCoV NTAb, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.

	Primary	Booster	P-Value
nCoV NTAb			
The positive rate	12(57.1)	18(85.7)	0.085
Antibody level	11.1(8.4-16.0)	48.8(16.8-143.4)	<0.001
nCoV S-RBD			
The positive rate	14(66.7)	19(90.5)	0.133
Antibody level	24.3(7.2-48.9)	142.5(55.8-424.9)	< 0.001

Table 4 The dynamic changes of antibody in 21 patients performing twice antibody tests.

Data was presented as median (interquartile range) or frequencies(%). Antibody level above 10.0 AU/mL was regarded as positive, while antibody level below 10.0 AU/mL was regarded as negative. nCoV NTAb, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.

characteristic	Positive	Negative
Ν	12	9
Age,year	53.5(48.8-67.8)	57.0(46.5-66.0)
Gender, male	7(58.3)	5(55.6)
BMI	24.4±4.8	25.4±3.4
Time interval	39(32-82)	100(43-138)
Presence of cirrhosis	6(50.0)	8(88.9)
Comorbidities	5(41.7)	3(33.3)

Table 5 Demographic and clinical characteristics of nCoV NTAb positive and negative after primary immunity in 21 patients.

Data was presented as median (interquartile range) or frequencies(%). Time interval meant the time (days) between the completion of primary immunity and the collection of serological samples. BMI, Body Mass Index.

characteristic	Positive	Negative
N	14	7
Age,year	53.5(47.8-67.3)	57.0(48.0-74.0)
Gender, male	8(57.1)	4(57.1)
BMI	24.9±4.7	24.6±3.3
Time interval	39(32-90)	100(56-136)
Presence of cirrhosis	8(57.1)	6(85.7)
Comorbidities	6(42.9)	2(28.6)

Table 6 Demographic and clinical characteristics of nCoV S-RBD positive and negative after primary immunity in 21 patients.

Data was presented as median (interquartile range) or frequencies(%). Time interval meant the time (days) between the completion of primary immunity and the collection of serological samples. BMI, Body Mass Index.



Figure 1 Study flow chart.



Figure 2 The humoral immune response of COVID-19 vaccine in Primary and Booster groups among patients with chronic liver disease

Figure A revealed the positive rate of nCoV NTAb in Primary and Booster groups. Figure B revealed the level of nCoV NTAb in Primary and Booster groups. Figure C revealed the positive rate of nCoV S-RBD in Primary and Booster groups. Figure D revealed the level of nCoV S-RBD in Primary and Booster groups. Antibody level over 10.0 AU/mL was thought positive, while antibody level less than 10.0 AU/mL was thought negative. nCoV NTAb, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.



Figure 3 The level of nCoV NTAb and nCoV S-RBD in Primary and Booster groups among patients with no cirrhosis and cirrhosis.

Figure A showed the level of nCoV NTAb and Figure B showed the level of nCoV S-RBD. nCoV NTAb, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.



Figure 4 The dynamic changes of antibody in 21 patients performing twice antibody tests.

Figure A revealed the positive rate of nCoV NTAb and nCoV S-RBD in Primary and Booster groups. Figure B revealed the level of nCoV NTAb and nCoV NTAb in Primary and Booster groups. Figure C revealed the dynamic change of nCoV NTAb after primary immunity and booster immunity. Figure D revealed the dynamic change of nCoV S-RBD after Primary immunity and booster immunity. Antibody level over 10.0 AU/mL was thought positive, while antibody level less than 10.0 AU/mL was thought negative. nCoV NTAb, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.











Booster